journal article·2018-02-17Open access

miR-133 involves in lung adenocarcinoma cell metastasis by targeting FLOT2

Guangxia Wei, Yahuan Xu, Tao Peng, Jie Yan

Abstract

BACKGROUND: Dysregulated microRNAs (miRNAs) reported to involve into the oncogenesis and progression in various human cancers. However, the roles and mechanism of miR-133 in lung adenocarcinoma remain largely unclear. METHODS: In this study, qPCR assay and western blot were used to detect the expression levels of miR-133, Akt and FLOT2. Luciferase reporter assay was used to identify the target role of miR-133 on FLOT2. The cell invasion and the migration capability were performed using the transwell invasion assay and wound healing assay. RESULTS: We found that miR-133 expression levels were downregulated in human lung adenocarcinoma specimens and cell lines compared with the adjacent normal tissues and normal human bronchial epithelial cell. miR-133 significantly suppressed metastasis of lung adenocarcinoma cells in vitro. Furthermore, FLOT2 (flotillin-2) identified as a direct target of miR-133, and FLOT2 expression levels were inversely correlated with miR-133 expression levels in human lung adenocarcinoma specimens. And the restoration studies suggested FGF2 as a downstream effector of miR-133 which acted through Akt signalling pathway. CONCLUSIONS: Our study revealed the mechanism that miR-133 suppresses lung adenocarcinoma metastasis by targeting FLOT2 via Akt signalling pathway, implicating a potential prognostic biomarker and therapeutic target for lung adenocarcinoma treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Caveolin-1 and cellular processes · MicroRNA in disease regulation · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiothoracic Surgery, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei Province, China

References (29)

Show source-provided references
1. 10.1001/jama.291.10.123810.1001/jama.291.10.1238 ↗
2. 10.3322/caac.2000610.3322/caac.20006 ↗
3. 10.1159/00036633710.1159/000366337 ↗
4. 10.1016/j.ccm.2011.08.01710.1016/j.ccm.2011.08.017 ↗
5. Li Z · Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc · 2015 · 18 · 4310.1007/s10120-014-0340-8 ↗
6. 10.3727/096504013X1377548674933510.3727/096504013X13775486749335 ↗
7. 10.1159/00035452710.1159/000354527 ↗
8. 10.1111/jcmm.1231710.1111/jcmm.12317 ↗
9. 10.3892/or.2014.297310.3892/or.2014.2973 ↗
10. 10.1371/journal.pone.006121210.1371/journal.pone.0061212 ↗
11. 10.1371/journal.pone.007261510.1371/journal.pone.0072615 ↗
12. 10.1158/0008-5472.CAN-13-219310.1158/0008-5472.CAN-13-2193 ↗
13. Tao J · Oncol Rep · 2012 · 27 · 1967
14. 10.3109/00365599.2012.74882110.3109/00365599.2012.748821 ↗
15. 10.1016/j.cellsig.2014.08.01210.1016/j.cellsig.2014.08.012 ↗
16. 10.1038/nprot.2007.3010.1038/nprot.2007.30 ↗
17. Wang YL · Int J Clin Exp Pathol · 2015 · 8 · 601
18. 10.3892/or.2015.382610.3892/or.2015.3826 ↗
19. 10.1007/s13277-014-2229-x10.1007/s13277-014-2229-x ↗
20. 10.18632/oncotarget.547810.18632/oncotarget.5478 ↗
21. 10.18632/oncotarget.388610.18632/oncotarget.3886 ↗
22. 10.1016/j.ejcb.2007.03.00310.1016/j.ejcb.2007.03.003 ↗
23. 10.1186/1479-5876-11-19010.1186/1479-5876-11-190 ↗
24. 10.1007/s13277-014-2343-910.1007/s13277-014-2343-9 ↗
25. 10.1007/s00432-014-1874-110.1007/s00432-014-1874-1 ↗
26. Liu Y · Int J Clin Exp Pathol · 2015 · 8 · 622
27. 10.1186/1471-2407-14-10010.1186/1471-2407-14-100 ↗
28. 10.1038/onc.2012.49910.1038/onc.2012.499 ↗
29. 10.1007/s12253-015-0023-810.1007/s12253-015-0023-8 ↗